A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers.

Trial Profile

A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs MM 111 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2012 Actual patient number (20) added as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2011 Phase changed from I/II to I, disease changed from Advanced Her2 Amplified Cancers to Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers, phase 2 tt. part removed, inclusion/ exclusion criterion modified.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top